Our cohort consisted of 74 patients with sarcoidosis, including different clinical presentations, and IHC staining was scored using the method described by Pizinni et al. Therefore, in our opinion, the aforementioned possible confounders are unlikely to explain the difference in sarcoidosis patients with S6K activation. This evidence concerns the gene RPS6KB1 and sarcoidosis.